Sun Pharma Previews Long-Term UNLOXCYT Follow-Up at ASCO 2026
Key Takeaways:
- Sun Pharma will present long-term follow-up data from the pivotal trial of UNLOXCYT (cosibelimab-ipdl) at the 2026 ASCO Annual Meeting.
- The data focus on patients with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation.
- The presentations are intended to further characterize the durability of response and safety profile of the PD-L1 inhibitor following its recent FDA approval.
UNLOXCYT received FDA approval in 2025 based on results from the multicenter Phase 1 trial evaluating cosibelimab, an investigational PD-L1–targeting monoclonal antibody. The approval was supported by objective response rates and durability of response observed in patients with advanced cSCC, a disease that can become difficult to manage once it is no longer amenable to local therapy.
According to Sun Pharma, the ASCO presentations will provide additional follow-up on efficacy outcomes, including duration of response and overall survival measures, as well as updated safety findings. Long-term follow-up data are often closely watched in immuno-oncology because they can help determine whether responses remain durable over time and whether late-emerging toxicities become apparent with extended treatment exposure.
Cutaneous squamous cell carcinoma is the second most common form of skin cancer, though advanced disease represents a relatively small subset of cases. For patients with unresectable or metastatic tumors, immune checkpoint inhibitors targeting PD-1 or PD-L1 have become an increasingly important treatment option over the past several years. Cosibelimab joins a growing field of immunotherapies already used in advanced cSCC, including cemiplimab and pembrolizumab.
Sun Pharma stated that the updated analyses will be presented during poster sessions at the ASCO meeting in Chicago.